Intercept Pharmaceuticals, Inc. (ICPT)
(Delayed Data from NSDQ)
$89.92 USD
+1.71 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $89.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ICPT]
Reports for Purchase
Showing records 101 - 120 ( 867 total )
Industry: Medical - Biomedical and Genetics
4Q20 Recap; Timeline to Resolving Uncertainties Around PBC and NASH Remains Uncertain; Maintain Sell
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Following CMO Resignation, We No Longer Believe a Viable Regulatory Path in NASH Exists; Downgrade to Sell
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Progress Expected For Ocaliva in PBC and NASH in 2021 But Uncertainties Remain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department